Opthea Files Notice of Annual General Meeting
October 16, 2024 07:00 ET
|
Opthea Limited
Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s...
Opthea Wet AMD Program to be Presented at Innovate Retina
October 10, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight
October 08, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight VEGFR2 (vascular endothelial growth factor receptor...
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
October 08, 2024 07:00 ET
|
Opthea Limited
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE)...
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
September 30, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Joins the S&P/ASX 300 Index
September 23, 2024 07:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
September 18, 2024 07:30 ET
|
Opthea Limited
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
September 10, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Executive Leadership Changes and Senior Hires
September 05, 2024 06:00 ET
|
Opthea Limited
Daniel Geffken and Mike Campbell respectively appointed CFO ad interim and CCOThree senior leaders appointed for Biometrics, Clinical Operations and Market AccessDeepening retina and launch expertise...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
September 03, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...